Evidence map›Paper›PMID 28534194›Full record

ArticleJournal of computer-aided molecular design2017

Assessing protein-ligand binding modes with computational tools: the case of PDE4B.

Gülşah Çifci, Viktorya Aviyente, E Demet Akten, Gerald Monard

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gülşah ÇifciDepartment of Chemistry, Boğaziçi University, 34342, Bebek, Istanbul, Turkey.
Viktorya AviyenteDepartment of Chemistry, Boğaziçi University, 34342, Bebek, Istanbul, Turkey.
E Demet AktenBioinformatics and Genetic, Kadir Has University, 34083, Cibali, Istanbul, Turkey.
Gerald MonardUniversité de Lorraine, UMR 7565 SRSMC, Boulevard des Aiguillettes, B.P. 70239, 54506, Vandoeuvre-les-Nancy, France. Gerald.Monard@univ-lorraine.fr.ORCID http://orcid.org/0000-0002-3378-3481

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a first step in the discovery of novel potent inhibitor structures for the PDE4B family with limited side effects, we present a protocol to rank newly designed molecules through the estimation of their IC[Formula: see text] values. Our protocol is based on reproducing the linear relationship between the logarithm of experimental IC[Formula: see text] values [[Formula: see text](IC[Formula: see text])] and their calculated binding free energies ([Formula: see text]). From 13 known PDE4B inhibitors, we show here that (1) binding free energies obtained after a docking process by AutoDock are not accurate enough to reproduce this linear relationship; (2) MM-GB/SA post-processing of molecular dynamics (MD) trajectories of the top ranked AutoDock pose improves the linear relationship; (3) by taking into account all representative structures obtained by AutoDock and by averaging MM-GB/SA computations on a series of 40 independent MD trajectories, a linear relationship between [Formula: see text](IC[Formula: see text]) and the lowest [Formula: see text] is achieved with [Formula: see text].

Indexed as

LigandsBinding SitesCyclic Nucleotide Phosphodiesterases, Type 4HumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructurePhosphodiesterase 4 InhibitorsProtein BindingProtein ConformationQuantitative Structure-Activity RelationshipRolipramSmall Molecule LibrariesThermodynamicsCyclic Nucleotide Phosphodiesterases, Type 4LigandsPDE4B protein, humanPhosphodiesterase 4 InhibitorsRolipramSmall Molecule LibrariesIC50MM-GB/SAMolecular dockingMolecular dynamicsPDE4B

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.